Two studies discussed the feasibility of different parameters for the infusion of a product for patients with primary immunodeficiency disorder in abstracts prepared for the American Academy of ...
Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Cutaquig provided safe and effective dosing flexibility for patients with primary immunodeficiency ...
image: Octapharma USA presented research at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting evaluating the efficacy and safety of cutaquig® (Immune Globulin Subcutaneous ...
PARAMUS, N.J. (May 18, 2023) – An Octapharma-sponsored study published recently in The Journal of Clinical Immunology concludes that cutaquig ® (Immune Globulin Subcutaneous [Human]-hipp, 16.5% ...
Please provide your email address to receive an email when new articles are posted on . One of my highly intelligent residents recently inquired about my personal fluidic settings for our phaco ...
IRVINE, Calif.--(BUSINESS WIRE)--Medical device developer Capillary Biomedical, Inc. (CapBio) has presented highly favorable clinical feasibility study results for its SteadiFlow cannula technology at ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results